Astonishingly, in recent months we have discovered (along with Pasteur and our network of global experts) that our approach for ALS is totally applicable to COVID-19 as SARS-CoV-2 uses the same enzymes! Glucosylceramide synthase (GCS) and glucosylcéramidase (GCase) are essential for the entry and exit of envelope viruses in and out of cells, and critical also for cellular metabolism. Thus, ambroxol and related drugs could potentially be used in the treatment of COVID, and for recovery, where NeuroMuscular Junctions (NMJs), muscle function and metabolism are impaired. The rational is really innovative using metabolomics (glycosphingolipids and associated sialic acids are key for viruses) and could also target fibrosis, where ceramide is a key driver. We are exploring clinical trials in India. Collaborations are welcomed.